VistaGen Therapeutics Inc. (NASDAQ:VTGN) saw a downside of -0.89% to $0.18 after subtracting $0.0 on Tuesday. The 5-day average trading volume is 3,712,467 shares of the company’s common stock. It has gained $0.1950 in the past week and touched a new high 1 time within the past 5 days. An average of 6,671,442 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 6,774,103.
VTGN’s 1-month performance is 69.99% or $0.0793 on its low of $0.0900 reached on 12/28/22. The company’s shares have touched a 52-week low of $0.08 and high of $1.79, with the stock’s rally to the 52-week high happening on 01/18/23. YTD, VTGN has achieved 73.79% or $0.0740 and has reached a new high 6 times. However, the current price is down -90.09% from the 52-week high price.
VTGN stock investors last saw insider trading activity on Aug 18.Venrock Healthcare Capital Par (10% Owner) most recently sold 60,000 shares at $0.89 per share on Jul 12. This transaction cost the insider $53,400.
VTGN stock has a beta of 0.62. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 1.28.
VistaGen Therapeutics Inc.’s quick ratio for the period ended September 29 was 6.10, with the current ratio over the same period at 6.10. The firm’s gross profit as reported stood at $48.89 million against revenue of $1.11 million.
For the quarterly period ending September 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 24.66% to -$17.48 million, while revenue of -$19.78 million was -13.16% off the previous quarter. Analysts expected VTGN to announce -$0.07 per share in earnings in its latest quarter, but it posted -$0.08, representing a -14.30% surprise. EBITDA for the quarter stood at more than -$17.46 million. VTGN stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 11.1 million, with total debt at $3.57 million. Shareholders hold equity totaling $206.84 million.
Let’s look briefly at VistaGen Therapeutics Inc. (VTGN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 23 January was 62.21% to suggest the stock is trending Neutral, with historical volatility in this time period at 120.02%.
The stock’s 5-day moving average is $0.1710, reflecting a -3.70% or -$0.0068 change from its current price. VTGN is currently trading +82.47% above its 20-day SMA, +1.26% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +57.19% and SMA200 by-86.17%.
Stochastic %K and %D was 78.39% and 74.83% and the average true range (ATR) pointed at 0.0201. The RSI (14) points at 60.91%, while the 14-day stochastic is at 75.68% with the period’s ATR at 0.0204. The stock’s 9-day MACD Oscillator is pointing at 0.0065 and 0.0125 on the 14-day charts.
In the most recent analyst report for VistaGen Therapeutics Inc. (NASDAQ: VTGN), William Blair downgraded it to a Mkt perform rating. They previously had an Outperform rating on the stock. Analysts offering their rating for VTGN stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate VTGN as a “sell,”, while 2 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 0 have offered a “buy” rating.
What is VTGN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $0.25 and a high of $0.25, with their median price target at $0.25. Looking at these predictions, the average price target given by analysts is for VistaGen Therapeutics Inc. (VTGN) stock is $0.25.